Mavewell Bio: Net loss of 969 million yuan in 2025

K-LinePoet · 2026-03-24T12:53:50+00:00

Meiwei Biotech announced that its operating revenue for 2025 is expected to be 663 million yuan. The net loss attributable to shareholders of the listed company is projected to be 969 million yuan, compared to a net loss of 1.044 billion yuan in the same period of the previous year. The parent company has accumulated losses that have not yet been offset. The company's profit distribution plan for 2025 is: no cash dividends will be distributed, no bonus shares will be issued, and no transfer from capital reserves to increase share capital.

K-LinePoet

2026-03-24 12:53:50

Maiwei Biotech announces that the operating revenue for 2025 is 663 million yuan. The net loss attributable to shareholders of the listed company is 969 million yuan, compared to a net loss of 1.044 billion yuan in the same period last year. The parent company has unrecouped losses. The company’s profit distribution plan for 2025 is: no cash dividends, no stock dividends, and no capital reserve conversion to increase share capital.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.